About
Our research is focused on the functional role and molecular actions of cellular glycosylation and carbohydrate-binding proteins (lectins), in particular galectins, in cancer development, progression and metastasis. We also have a strong interest in translational development of galectin-targeted novel therapeutics for cancer. Our research has led to the formation of a University spin-out biotech company, GALYTX, to accelerate clinical development of several novel galectin inhibitors identified and developed in our laboratory. Our research has been supported by various national and international funding agencies including MRC, CRUK, BBSRC, Wellcome Trust, Northwest Cancer Research Fund, Royal Society, American Institute for Cancer Research, World Cancer Research Fund, and Mizutani Foundation for Glycoscience